Mabwell Wins NMPA Nod to Test Novel Autoimmune Antibody 9MW5211 in VitiligoTip Ranks·Jul 15 at 07:08 AM02493-0.77%
Mabwell says China NMPA clears 9MW5211 vitiligo trial applicationPUBT·Jul 15 at 07:03 AM02493-0.77%688062+1.16%
Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancersPUBT·Jun 23 at 07:00 PM688062+1.16%02493-0.77%
Mabwell reshapes senior leadership to bolster pharma growth and governanceTip Ranks·Jun 18 at 09:44 AM02493-0.77%
Mabwell Showcases Promising Nectin-4 ADC Data in Cervical Cancer at ESMO Gynae 2026Tip Ranks·Jun 18 at 09:43 AM688062+1.16%02493-0.77%
Mabwell Proposes New Board Line-Up as Current Directors RetireTip Ranks·May 31 at 07:07 AM02493-0.77%
Mabwell Calls 2026 Extraordinary Meeting to Overhaul Governance and MandatesTip Ranks·May 31 at 07:07 AM02493-0.77%
23:30 ETMabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentationsprnewswire·May 21 at 10:32 PM688062+1.16%02493-0.77%
